Conclusion of a non-exclusive pharmaceutical discount agreement for OLIMEL and interchangeable finished medicinal products

Summary

The tender concerns the conclusion of non-exclusive pharmaceutical discount agreements by DAK-Gesundheit with interested pharmaceutical companies. The agreements cover OLIMEL finished medicinal products, excluding electrolyte-free products with a strength of 7.6% (KPG), and interchangeable finished medicinal products under ATC code B05BA10. The agreements are intended to run from 1 October 2026 to 30 September 2028 and will end automatically if an exclusive agreement for the same active substance enters into force. Detailed participation and submission requirements must be checked in the official tender documents.